mTOR: taking cues from the immune microenvironment.

PubWeight™: 1.38‹?› | Rank: Top 10%

🔗 View Article (PMC 2729523)

Published in Immunology on August 01, 2009

Authors

Greg M Delgoffe1, Jonathan D Powell

Author Affiliations

1: Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Articles citing this

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22

Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 2.85

How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol (2010) 2.11

mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 1.74

Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68

The metabolic life and times of a T-cell. Immunol Rev (2010) 1.57

Metabolic shifts in immunity and inflammation. J Immunol (2010) 1.45

The complex interplay between autophagy, apoptosis, and necrotic signals promotes T-cell homeostasis. Immunol Rev (2010) 1.35

Metabolic control of the Treg/Th17 axis. Immunol Rev (2013) 1.26

The lipopolysaccharide core of Brucella abortus acts as a shield against innate immunity recognition. PLoS Pathog (2012) 1.17

Regulation of glucose metabolism in T cells: new insight into the role of Phosphoinositide 3-kinases. Front Immunol (2012) 0.97

Calorie restriction and stroke. Exp Transl Stroke Med (2011) 0.95

Multifaceted regulation of T cells by CD44. Commun Integr Biol (2010) 0.94

Modulation of T Cell Metabolism and Function through Calcium Signaling. Front Immunol (2013) 0.93

The role of mTOR signaling pathway in spinal cord injury. Cell Cycle (2012) 0.90

Low dose rapamycin exacerbates autoimmune experimental uveitis. PLoS One (2012) 0.89

Changing the energy of an immune response. Am J Clin Exp Immunol (2013) 0.88

Induction and stability of the anergic phenotype in T cells. Semin Immunol (2013) 0.87

Mammalian target of rapamycin complex 2 regulates invariant NKT cell development and function independent of promyelocytic leukemia zinc-finger. J Immunol (2014) 0.87

Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat Rev Rheumatol (2016) 0.86

Mechanisms that regulate peripheral immune responses to control organ-specific autoimmunity. Clin Dev Immunol (2011) 0.83

Protective role of p70S6K in intestinal ischemia/reperfusion injury in mice. PLoS One (2012) 0.83

Inhibition of ERK1/2 worsens intestinal ischemia/reperfusion injury. PLoS One (2013) 0.83

T cell Receptor Signal Transduction in T lymphocytes. J Clin Cell Immunol (2012) 0.83

The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses. Nutrients (2013) 0.82

mTORC1-S6K activation by endotoxin contributes to cytokine up-regulation and early lethality in animals. PLoS One (2010) 0.82

The battle over mTOR: an emerging theatre in host-pathogen immunity. PLoS Pathog (2012) 0.81

Anti-proliferation effects of Sirolimus sustained delivery film in rabbit glaucoma filtration surgery. Mol Vis (2011) 0.81

Ghrelin inhibits the differentiation of T helper 17 cells through mTOR/STAT3 signaling pathway. PLoS One (2015) 0.80

Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes. Methods Mol Biol (2012) 0.79

Intrinsic and Tumor Microenvironment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and Function. Front Immunol (2016) 0.78

Interface of signal transduction inhibition and immunotherapy in melanoma. Cancer J (2010) 0.77

Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic target. Oncoimmunology (2012) 0.77

Hepatic stellate cells increase the immunosuppressive function of natural Foxp3+ regulatory T cells via IDO-induced AhR activation. J Leukoc Biol (2016) 0.76

Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation. World J Transplant (2016) 0.75

Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond. Adv Nutr (2016) 0.75

The role of ubiquitin ligases in the control of organ specific autoimmunity. Am J Clin Exp Immunol (2012) 0.75

Articles cited by this

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05

Regulatory T cells and immune tolerance. Cell (2008) 18.77

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83

The danger model: a renewed sense of self. Science (2002) 13.85

The B7 family revisited. Annu Rev Immunol (2005) 13.51

mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48

Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53

A theory of self-nonself discrimination. Science (1970) 7.99

CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol (1998) 7.31

CD4 T cells: fates, functions, and faults. Blood (2008) 7.03

Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49

Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A (2002) 6.19

The two TORCs and Akt. Dev Cell (2007) 6.17

The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 6.07

T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62

Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol (2008) 4.69

The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52

The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 4.44

Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol (2006) 4.23

Expanding mTOR signaling. Cell Res (2007) 4.01

Immunopharmacology of rapamycin. Annu Rev Immunol (1996) 3.86

TOR signaling. Sci STKE (2003) 3.61

Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol (2008) 3.43

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13

Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09

Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61

Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood (2008) 2.53

A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol (2007) 2.53

Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science (1969) 2.48

A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci (1975) 2.33

Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant (2005) 2.32

Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol (1999) 2.26

Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 2.12

Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol (2004) 2.10

Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol (2007) 2.08

Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol (2006) 1.90

Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol (2006) 1.81

Toll-like receptors and acquired immunity. Semin Immunol (2004) 1.79

Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol (2008) 1.71

De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol (2008) 1.52

The role of cell division in the induction of clonal anergy. Immunol Today (1992) 1.46

Intracellular signaling by Akt: bound to be specific. Sci Signal (2008) 1.39

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol (2007) 1.35

Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol (2008) 1.34

CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol (2000) 1.34

Is cancer dangerous to the immune system? Semin Immunol (1996) 1.31

Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood (2002) 1.26

IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol (2008) 1.22

Dissecting the mechanism of T-cell anergy with immunophilin ligands. Curr Opin Investig Drugs (2006) 1.15

The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol (2004) 1.08

Th1 cell anergy and blockade in G1a phase of the cell cycle. J Immunol (1993) 1.07

T cell effector function and anergy avoidance are quantitatively linked to cell division. J Immunol (2000) 1.06

Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol (2001) 1.04

TCR engagement in the absence of cell cycle progression leads to T cell anergy independent of p27(Kip1). Eur J Immunol (2001) 1.01

How does the immune system distinguish self from nonself? Semin Immunol (2000) 1.01

Clonal anergy is maintained independently of T cell proliferation. J Immunol (2002) 1.00

mTOR: dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans (2009) 0.94

Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev (2006) 0.90

Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int (2007) 0.83

Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transpl Immunol (2008) 0.79

Articles by these authors

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59

Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36

Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74

Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol (2006) 3.32

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69

A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol (2007) 2.53

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17

Anergic T cells are metabolically anergic. J Immunol (2009) 2.12

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99

Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc Natl Acad Sci U S A (2011) 1.86

mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 1.74

The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity (2010) 1.64

A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity (2011) 1.58

Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J Immunol (2009) 1.45

Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol (2008) 1.35

mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation. J Clin Invest (2015) 1.18

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2011) 1.16

Retracted Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol (2013) 1.09

Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J Immunol (2012) 1.08

The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol (2004) 1.08

Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell (2003) 1.08

Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation. Mol Immunol (2009) 0.98

Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription. J Immunol (2006) 0.98

Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression. J Inflamm (Lond) (2008) 0.96

Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood (2007) 0.96

Differential regulation of hyaluronan-induced IL-8 and IP-10 in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2006) 0.96

PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol (2011) 0.96

The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion. Am J Respir Cell Mol Biol (2008) 0.95

De novo DNA methylation is required to restrict T helper lineage plasticity. J Biol Chem (2012) 0.94

Pulmonary vaccination as a novel treatment for lung fibrosis. PLoS One (2012) 0.91

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. Front Immunol (2012) 0.91

Sprouty-2 regulates HIV-specific T cell polyfunctionality. J Clin Invest (2014) 0.90

Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection. Curr Opin Organ Transplant (2014) 0.89

Hyaluronan fragments induce IFNβ via a novel TLR4-TRIF-TBK1-IRF3-dependent pathway. J Inflamm (Lond) (2013) 0.89

Sensing the immune microenvironment to coordinate T cell metabolism, differentiation & function. Semin Immunol (2013) 0.87

Adenosine and anergy. Autoimmunity (2007) 0.86

Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor. Am J Respir Cell Mol Biol (2011) 0.83

NF-kappa B activation mediates the cross-talk between extracellular matrix and interferon-gamma (IFN-gamma) leading to enhanced monokine induced by IFN-gamma (MIG) expression in macrophages. J Biol Chem (2002) 0.82

Quieting T cells with Slfn2. Nat Immunol (2010) 0.81

Genetic and biochemical regulation of CD4 T cell effector differentiation: insights from examination of T cell clonal anergy. Immunol Res (2010) 0.80

An Fc domain protein-small molecule conjugate as an enhanced immunomodulator. J Am Chem Soc (2014) 0.80

Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes. Methods Mol Biol (2012) 0.79

Regulation of CD4⁺ and CD8⁺ effector responses by Sprouty-1. PLoS One (2012) 0.78

Slc7a5 helps T cells get with the program. Nat Immunol (2013) 0.77

Selective activation of antigen-experienced T cells by anti-CD3 constrained on nanoparticles. J Immunol (2013) 0.77

Targeted immunosuppression: no longer naïve. Clin Immunol (2011) 0.75